Wikipedia -WSS

Wikipedia

author：explore 2025-09-28 22:53:33 - browse：8626

Stock exchange — Drew Angerer/Getty Images

Sage Therapeutics said Monday that it may need to reduce costs, including through employee layoffs, following the Food and Drug Administration’s denial of its rapid-acting drug for major depressive disorder.

On Friday, the agency granted market clearance for the drug, called Zurzuvae, to treat women with postpartum depression, a smaller commercial market. Sage failed to convince regulators to also approve the drug for depression, a broader condition.

“We don’t agree with the FDA review,” Sage CEO Barry Greene said during an earnings call, a point he made repeatedly. “We are evaluating the [FDA’s response letter] and as soon as we can provide more clarity, we will, on what the next steps are.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： First Opinion Podcast: How to protect health care in times of war

explore

WSS

Websites selling Wegovy, Zepbound ingredients targeted by FDA

Study gives hint on South Asians’ higher risk of cardiovascular disease

Congress considering partial increase for doctor pay in Medicare

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

Latigo launches with $135 million for Vertex

Readout Newsletter: What happened with Sarepta's Duchenne data

focus

Wikipedia

focus

23andMe had bad news about my health. I wish a person had delivered it

FDA has safety concerns on CRISPR

In age of alternative facts, a scholarly course on calling out crap

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Hepatitis C has a cure — but many Americans still lack access to it

AMAs digital advisors table RPM coding reform proposal, again

As demand for Covid shots wanes, Moderna seeks its next success

FDA has safety concerns on CRISPR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

FDA has safety concerns on CRISPR

entertainment

AMAs digital advisors table RPM coding reform proposal, again

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Artificial intelligence use in health care faces greater scrutiny in 2024

Long Covid research funding gets a major boost from NIH

Emergency medicine has repudiated 'excited delirium.' Now what?

Long Covid research funding gets a major boost from NIH

explore

explore

explore

entertainment